Retina/Vitreous News

SAN FRANCISCO — Data provided by the Vision Loss Expert Group, an international, ophthalmic epidemiology reference group, shows an encouraging trend towards increased coverage of refractive error and cataract surgery globally.

In this Healio Video Perspective from the AAO meeting, Diana V. Do, MD, overviews positive 96-week efficacy and safety data from the PHOTON study investigating aflibercept 8 mg in patients with diabetic macular edema.

SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Sam Barone, MD, of Nanoscope Therapeutics discusses efficacy and safety data for the company’s MCO-010 optogenetic therapy.

Adults with long-standing thyroid eye disease and low clinical activity scores had greater reductions in proptosis with teprotumumab compared with placebo, according to data published in The Journal of Clinical Endocrinology & Metabolism.

Patients with diabetic macular edema treated with intravitreal aflibercept for up to 24 months achieved functional and anatomical improvements, even with reduced injection frequency, according to study results in Ophthalmology and Therapy.

Despite the promise of OCTA as a valuable tool in the evaluation of diabetic retinopathy and its complications, challenges remain and more research is needed to standardize its use in clinical trials, according to a published review.

EyeBio closed an extension to its Series A financing, ending with $130 million raised, according to a press release.

The first-in-human trial assessing the safety and efficacy of the PRIMA photovoltaic retinal stimulation microchip for severe central vision impairment due to dry age-related macular degeneration showed positive outcomes at 4 years.

Longer diabetic retinopathy screening intervals of 3 to 5 years may be safe under certain circumstances and may reduce health care costs and workload, according to a systematic review published in Acta Ophthalmologica.

SAN FRANCISCO — In this Healio Video Perspective from Eyecelerator@AAO, Megan Baldwin, PhD, of Opthea, shares an update on sozinibercept, a VEGF-C/D inhibitor for the treatment of neovascular age-related macular degeneration.